Doctor Xueyi Wu

Fuwai Hospital, CAMS and PUMC, Beijing (China)

Follow

Contributor content

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial

Presentation

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial

ESC 365 is supported by

novartis

Explore sponsored resources